Posts Archive

DREAMM 9 - Transplant Ineligible - Newly Diagnosed Multiple Myeloma Part 1: Dose escalation and cohort expansion Part 2: Dose selection...

RRMM NCT04123418: Phase 1: A Study of WVT078 in Patients With Multiple Myeloma (MM) A Study of WVT078 in Patients With Multiple Myeloma...

NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (CarMob)...

TRIMM-2 study A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment...

NCT038282: Phase 1 - Dose Esc Study Belantamab mafodotin (GSK2857916) in Japanese With Refr MM Belantamab mafodotin (GSK2857916) is a...

(LUMMICAR STUDY 1) NCT03975907: Phase 1/2 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma...

NCT04155749: Phase 1: Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma Master Protocol for the Phase 1 Study...

ABBV-383 (formerly TNB-383B) TNB-383B, a Bispecific Antibody Targeting BCMA BCMA x CD3 T-cell engaging bispecifc antibody RRMM...

AMG 420 To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous...

NCT04182581: Phase 1: A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma A Study of...

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma Kd This...

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma This early phase I trial studies the side effects of...

RRMM Phase A: Safety Run-in to test the safety of CART-BCMA + huCART19 as split-dose infusions after lymphodepleting chemotherapy with...

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma Study CC-93269-MM-001...

NCT03489525: Phase 1: MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228) The purpose of this study is to assess...

NCT03672318: Phase 1: Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma The body has different ways of fighting...

NCT03716856: Phase 1 - Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma A single arm, open-label...

NCT03502577: Phase 1 - BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent...

NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 Recruitment Status: Enrolling by invitation...